Dapagliflozin: Essential Guide To Uses, Dosage, Side Effects

Dapagliflozin, commonly known by the brand name Forxiga, belongs to a class of medications called

SGLT2 inhibitors

. These drugs help manage

type 2 diabetes

by preventing the kidneys from reabsorbing glucose back into the bloodstream, instead excreting it through urine. This action lowers blood sugar levels independently of insulin, making it suitable for adults and children aged 10 and older with type 2 diabetes. Approved as an adjunct to diet and exercise, dapagliflozin improves glycemic control and offers additional benefits like weight loss and cardiovascular protection.

What is dapagliflozin used for?

Dapagliflozin is primarily prescribed for people with

type 2 diabetes

to help control blood sugar levels when diet and exercise alone are insufficient. It is used as monotherapy or in combination with other diabetes medications such as metformin, insulin, sulfonylureas, or pioglitazone. Clinical studies demonstrate its efficacy in reducing HbA1c by promoting glycosuria, which also leads to modest weight reduction and blood pressure lowering.

• Glycemic control: Lowers fasting plasma glucose (FPG) and postprandial glucose (PPG) effectively, with sustained effects over 48 weeks when added to pioglitazone.
• Combination therapy: Enhances effects of other agents without increasing hypoglycemia risk significantly.
• Beyond diabetes: Shows promise in protecting kidney function and reducing cardiovascular events in high-risk patients.

It is not approved for

type 1 diabetes

due to risks like ketoacidosis, though trials like ATTEMPT in adolescents with type 1 diabetes indicate potential kidney and glycemic benefits under strict monitoring.

How does dapagliflozin work?

Dapagliflozin selectively inhibits the

sodium-glucose cotransporter 2 (SGLT2)

protein in the proximal tubules of the kidneys. SGLT2 is responsible for reabsorbing about 90% of filtered glucose. By blocking this transporter, dapagliflozin increases urinary glucose excretion (glucosuria), reducing blood glucose levels by 50-100g daily depending on plasma levels. This insulin-independent mechanism complements other therapies and may increase glucagon slightly, potentially protecting against hypoglycemia.

Key effects include:

• Reduced HbA1c by 0.5-1.0% across studies.
• Weight loss of 2-3kg due to caloric loss from glucose excretion.
• Mild osmotic diuresis lowering systolic blood pressure by 3-5 mmHg.

Dosage

The standard starting dose is

10mg once daily

in the morning, with or without food. For patients with volume depletion or on diuretics, consider 5mg initially. No dose adjustment is needed for mild renal impairment (eGFR ≥45 mL/min), but it is not recommended if eGFR <45 mL/min due to reduced efficacy. Tablets are film-coated and swallowed whole.

Patient Group	Recommended Dose	Notes
Adults with type 2 diabetes	10 mg once daily	Can reduce to 5 mg if needed for tolerability
Children ≥10 years	10 mg once daily	Approved for glycemic control
eGFR <45 mL/min	Not recommended	Monitor renal function

Side effects

Common side effects are related to its mechanism of increased urination and genital exposure to glucose:

• Genitourinary infections: Yeast infections (thrush) in 5-10% of users, more common in women. Treat with antifungals and maintain hygiene.
• Dehydration/volume depletion: Due to diuresis; symptoms include dizziness, hypotension. Risk higher in elderly or on diuretics.
• Urinary tract infections (UTIs): Increased frequency; stay hydrated.
• Other: Back pain, headache, increased LDL cholesterol mildly.

Rare but serious risks include

diabetic ketoacidosis (DKA)

(even with normal blood sugar),

Fournier’s gangrene

(necrotizing fasciitis of genitals), bone fractures, and amputations (class-wide for SGLT2 inhibitors). Hypoglycemia risk is low unless combined with insulin or sulfonylureas.

Who may be prescribed dapagliflozin?

Suitable for:

• Adults and children ≥10 years with type 2 diabetes.
• Patients overweight or obese, as it promotes weight loss.
• Those with heart failure or chronic kidney disease (CKD) for cardiorenal protection.
• Combination with metformin, DPP-4 inhibitors, GLP-1 agonists, or pioglitazone.

Not suitable for:

• Type 1 diabetes patients.
• Severe renal impairment (eGFR <45).
• History of DKA, severe infections, or dehydration-prone individuals.
• Pregnant or breastfeeding women (use contraception).

Key facts about dapagliflozin

• First SGLT2 inhibitor approved (2012 in Europe).
• Causes 300-400 mL extra urine daily; drink plenty of fluids.
• Does not cause hypoglycemia alone.
• Weight loss: Average 2-4 kg over 6-12 months.
• Blood pressure reduction: 3-6 mmHg systolic.
• May increase ketone production; monitor for DKA symptoms like nausea, fatigue.

Interactions

• Insulin/sulfonylureas: Increased hypoglycemia risk; reduce doses.
• Diuretics: Enhanced dehydration; monitor.
• NSAIDs/ACE inhibitors: Renal function effects.
• Alcohol: Increases dehydration/DKA risk.

Pregnancy, breastfeeding and fertility

Avoid during pregnancy (category C); animal studies show fetal renal harm. Not recommended breastfeeding as it passes into milk. Effective contraception advised for women of childbearing potential.

Alcohol

Limit intake; alcohol exacerbates dehydration and DKA risk. Monitor blood sugars closely.

Starting dapagliflozin

Take 10mg daily with breakfast. Expect increased urination initially. Monitor blood sugar, weight, and ketones. Healthcare team will adjust doses of other meds. Regular check-ups for renal function and infections essential.

Common questions

Will dapagliflozin cause weight loss?
Yes, typically 2-3kg due to glucose calorie loss (200-300 kcal/day excreted).

Does it affect blood pressure?
Yes, mild reduction via diuresis.

Can I drive on it?
Yes, unless hypoglycemic or dehydrated.

Frequently asked questions

Will I pee sugar (glucose) out?

Yes, dapagliflozin blocks kidney glucose reabsorption, leading to 50-70g daily excretion. This is normal and therapeutic; use test strips if concerned.

Will dapagliflozin cause low blood sugar (hypoglycaemia)?

Unlikely alone, as it doesn’t stimulate insulin. Risk rises with insulin/sulfonylureas; dose adjustments needed.

Will dapagliflozin cause me to lose weight?

Yes, average 2-3kg sustained weight loss from caloric deficit.

Will I need less diabetes medication?

Possibly; blood sugars improve, so other doses may reduce. Never stop without advice.

Does dapagliflozin cause thrush to my penis or vagina?

Increased risk (6-10%); treat promptly, use barrier hygiene.

Does dapagliflozin cause urinary tract infections?

Slightly increased; drink water, urinate after sex.

Does dapagliflozin cause dehydration?

Possible via diuresis; symptoms: thirst, dizziness. Hydrate well.

Does dapagliflozin affect the kidneys?

Protects long-term; initial eGFR dip reversible. Monitor if eGFR <60.

Does dapagliflozin cause heart problems?

No, reduces heart failure risk.

Does dapagliflozin affect the liver?

No specific issues; routine monitoring.

Does dapagliflozin cause a diabetic coma?

Rare DKA risk; symptoms: vomiting, breathlessness. Seek urgent care.

Is dapagliflozin safe while breastfeeding?

No, avoid.